DiaSorin SpA
MIL:DIA

Watchlist Manager
DiaSorin SpA Logo
DiaSorin SpA
MIL:DIA
Watchlist
Price: 107.45 EUR 3.22% Market Closed
Market Cap: 5.7B EUR
Have any thoughts about
DiaSorin SpA?
Write Note

Net Margin
DiaSorin SpA

14.5%
Current
17%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
14.5%
=
Net Income
167.7m
/
Revenue
1.2B

Net Margin Across Competitors

Country IT
Market Cap 5.7B EUR
Net Margin
14%
Country US
Market Cap 204.9B USD
Net Margin
14%
Country US
Market Cap 195.2B USD
Net Margin
29%
Country US
Market Cap 146.7B USD
Net Margin
16%
Country US
Market Cap 132.6B USD
Net Margin
11%
Country IE
Market Cap 110.6B USD
Net Margin
12%
Country US
Market Cap 64.7B USD
Net Margin
9%
Country DE
Market Cap 55.6B EUR
Net Margin
8%
Country CN
Market Cap 319.2B CNY
Net Margin
34%
Country US
Market Cap 41.6B USD
Net Margin
74%
Country US
Market Cap 37.7B USD
Net Margin
9%
No Stocks Found

DiaSorin SpA
Glance View

Market Cap
5.7B EUR
Industry
Health Care

DiaSorin SpA is a prominent Italian diagnostic solutions provider that has carved a niche in the healthcare industry. Founded in 1968, the company specializes in developing and manufacturing innovative diagnostic tests that facilitate disease detection, monitoring, and prevention. With a robust portfolio that ranges from immunodiagnostics to molecular diagnostics, DiaSorin has made significant strides in addressing urgent healthcare needs. The company operates globally, serving hospitals and laboratories across numerous countries, and has established a strong commitment to research and development. This focus not only enhances their product offerings but also positions them as a key player in rapidly evolving sectors like infectious disease testing, oncology, and autoimmune disorders. For investors, DiaSorin presents an intriguing opportunity rooted in its strategic growth initiatives and resilience amid market challenges. The company's strong track record of revenue growth and profitability, coupled with its agile response to emerging health crises—such as the COVID-19 pandemic—highlights its operational efficiency and adaptability. Furthermore, with an ongoing emphasis on expanding its product lines and seeking partnerships to drive innovation, DiaSorin is well positioned to capitalize on the increasing demand for advanced diagnostic solutions. As healthcare continues to evolve with technological advances and personalized medicine, DiaSorin’s capabilities and strong market presence make it a compelling consideration for investors looking for sustainable growth in the life sciences sector.

DIA Intrinsic Value
92.61 EUR
Overvaluation 14%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
14.5%
=
Net Income
167.7m
/
Revenue
1.2B
What is the Net Margin of DiaSorin SpA?

Based on DiaSorin SpA's most recent financial statements, the company has Net Margin of 14.5%.